A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma
NCT00627419
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
1
Enrollment
INDUSTRY
Sponsor class
Stopped
Study closed \& recruitment will not recommence
Conditions
Metastatic Melanoma
Interventions
DRUG:
IPI-504
Sponsor
Infinity Pharmaceuticals, Inc.